Results 101 to 110 of about 23,309 (224)

Optimized SPE‐HPLC‐FLD Method for the Simultaneous Determination of Olaparib, Propranolol, and Furosemide in Human Urine

Biomedical Chromatography, Volume 40, Issue 8, August 2026.
ABSTRACT Olaparib belongs to the PARP inhibitors and is widely used as an anticancer drug. Due to frequent side effects, it is usually co‐administered with an antihypertensive, such as propranolol and/or an antidiuretic, such as furosemide. In this study, a highly sensitive HPLC‐FLD method was developed for the simultaneous determination of the three ...
Georgios Kamaris, Antonia Kalagia, Catherine K. Markopoulou   +2 more
wiley   +1 more source

Phytochemical Profiling and Biological Evaluation of Anthyllis henoniana Organs: Integrated In Vitro and Molecular Docking Insights Into Antioxidant, Anti‐Inflammatory, and Cytotoxic Potential

Chemistry &Biodiversity, Volume 23, Issue 8, August 2026.
Anthyllis henoniana aerial parts were subjected to fractionated extraction. Methanolic fractions yielded high total phenolic and flavonoid contents with strong antiradical (anti‐DPPH) and neuroprotective (anti‐AChE) activities, whereas dichloromethane and cyclohexane fractions demonstrated potent cytotoxicity (anti‐MCF‐7, anti‐HCT‐116) and anti ...
Sabrine Jaber, Rami Rahmani, Jalloul Bouajila, Mohamed Debouba   +3 more
wiley   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5‐HT3 Receptor Antagonists: 2026 Update

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 387-393, August 2026.
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore, Melissa S. Bourque, Andreas Halman, José A. G. Agúndez, Cynthia A. Prows, Keiko Hikino, Matthias Schwab, Carolyn J. Oxencis, Dharmisha Chauhan, Meta H.M. Diekstra, Susie E. Long, Gillian C. Bell, Andrea Gaedigk, Michelle Whirl‐Carrillo, Teri E. Klein, Kelly E. Caudle, Rachel Conyers   +16 more
wiley   +1 more source

Effect of Late Second to Early Third Trimester of Pregnancy on the Activity of Renal Organic Anion Transporters (OAT1 and OAT3): A Biomarker Study

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 465-474, August 2026.
Pregnant individuals take drugs throughout pregnancy and many of these drugs (e.g., antivirals, antibiotics) are eliminated by renal organic anion transporters (OAT) 1 and OAT3. In vivo studies with OAT1/3 substrate drugs suggest that pregnancy increases renal OAT1/3 activities by 1.5‐ to 1.8‐fold.
Aarzoo Thakur, Jashvant D. Unadkat, Emily E. Fay, Nina Isoherranen, Mary F. Hebert   +4 more
wiley   +1 more source

FROM THE EDITOR

Фармакокинетика и Фармакодинамика, 2014
В настоящем номере представлен ряд актуальных обзоров, посвящённых изучению новых лекарственных средств и межлекарственному взаимодействию. Прежде всего, продолжается серия обзоров, связанных с исследованием функционирования и полиморфизма известных ...

doaj  

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 492-500, August 2026.
Coproporphyrin I (CPI) is an established endogenous biomarker for detecting drug–drug interactions (DDIs) involving the hepatic uptake transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1, gene SLCO1B1). While CPI has been extensively studied in healthy volunteers using controlled pre‐ and post‐OATP1B1‐inhibitor sampling, its applicability ...
Leila Potzel, Anina Zumtaugwald, Anna Bollinger, Chiara Jeiziner, Kurt E. Hersberger, Florine Wiss, Markus L. Lampert, Samuel S. Allemann, Henriette E. Meyer zu Schwabedissen, Céline K. Stäuble   +9 more
wiley   +1 more source

Review of existing methodologies to assess the activity of CYP2D6 using exogenous and endogenous markers

Фармакокинетика и Фармакодинамика, 2014
Peculiarities of functioning and polymorphism of cytochrome P450 isoenzyme CYP2D6. Existing methods for determining its activity using endogenous markers.
A. D. Abdrashitov, G. N. Gildeeva, G. V. Ramenskaya, V. V. Smirnov   +3 more
doaj  

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 531-541, August 2026.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 510-519, August 2026.
Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley   +1 more source

Benchmark of Open‐Access Star‐Allele Callers to Accurately Assess Haplotypes and Phenotypes in Pharmacogenetic Studies

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 520-530, August 2026.
Genetic polymorphisms are common in pharmacogenes, with sometimes important implications for drug metabolism. Assessing the correct enzyme phenotype from genetic data is thus a crucial step into the development of personalized medicine. Many bioinformatics star‐allele callers have been developed for this purpose of identifying the correct star alleles ...
Marc B. Gros‐La‐Faige, Emmanuelle Génin, Anthony F. Herzig   +2 more
wiley   +1 more source